Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1799

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 7A
Chunk 1799
---
31, 2024, the royalty period has not commenced, thus no accruals have been made.

(e) Litigation, Claims and Assessments

From time to time, the Company may be involved
in litigation relating to claims arising out of operations in the normal course of business. As of December 31, 2024, there were no pending
or threatened lawsuits that could reasonably be expected to have a material effect on the results of the Company’s operations.

12. SUBSEQUENT EVENTS

The Company has evaluated subsequent events through
March 27, 2025, which is the date the consolidated financial statements were issued.

January 2025 Offering

On January 28, 2025, the Company, entered into
a securities purchase agreement with certain institutional investors pursuant to which the Company sold, in a registered direct offering,
an aggregate of 204,312 shares of common stock at a purchase price of $5.105 per share (the “January 2025 Offering”). The
shares were offered pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-280796), which was declared
effective by the SEC on July 18, 2024, as supplemented by a prospectus supplement and accompanying base prospectus filed with the SEC
on January 30, 2025.

In a concurrent private placement, the Company also issued to the
investors unregistered warrants (the “January 2025 Warrants”) to purchase up to an aggregate of 408,621 shares of common
stock at an exercise price of $3.855 per share. The January 2025 Warrants are exercisable upon issuance, or January 30, 2025, and expire
twenty-four months from the date of issuance, or January 30, 2027.

As compensation for acting as the placement agent
for the January 2025 Offering, the Company paid H.C. Wainwright & Co., LLC a cash transaction fee equal to 7.5% of the aggregate
gross cash proceeds in the offering and a management fee equal to 1.0% of the aggregate gross cash proceeds in the offering. The Company
also issued to H.C. Wainwright & Co., LLC warrants (the “January 2025 Placement Agent Warrants”) to purchase up to 15,325
shares of common stock. The January 2025 Placement Agent Warrants have an exercise price equal to $6.382 per share and are exerc